Effectiveness of Recombinant Human Growth Hormone (rhGH) in the Treatment of Patients with Cystic Fibrosis
Intermediate End Points and Health Outcomes in rhGH-Treated Patients With CF (3)
This slide summarizes key findings from the systematic review about the correlation of pulmonary function and anthropometrics with mortality and HRQoL.
Percent predicted FEV1 is found to be a consistent predictor of mortality by multivariate regression analysis, with higher baseline scores or lesser rate of decline linked to better survival rates. Percent predicted FEV1 is also a multivariate predictor for many individual domains of HRQoL questionnaires, but the relationship to overall scores was not determined.
Keywords: regression | multivariate | univariate | anthropometrics | mortality | health related quality of life | HRQoL | QoL | quality of life | cystic fibrosis | CF | rhGH | recombinant human growth hormone | human growth hormone | HGH
- Phung OJ, Coleman CI, Baker EL, et al. Effectiveness of Recombinant Human Growth Hormone (rhGH) in the Treatment of Patients With Cystic Fibrosis. AHRQ Comparative Effectiveness Review No. 23 (Prepared by University of Connecticut-Hartford Hospital Evidence-based Practice Center under Contract No. 290-2007-10067-I). Rockville, MD: Agency for Healthcare Research and Quality; October 2010. AHRQ Publication No. 11-EHC003-EF.
Your slide tray is being processed.